Immunocore’s Post

Join our panel of experts as they discuss overcoming barriers to better care in #cholangiocarcinoma #CCA #oncology #MedEd #PeerVoice https://lnkd.in/dNRHyXUJ

In this video, we can see ovalbumin positive target cells have increased T-cell visits and these cells spend more time interacting with target cells. This is compared to cells without the surface protein which have reduced numbers of both. Livecyte allows us to compare and correlate treatments at a population level. Did you know that population heterogenity can affect your results? 👇 Watch our next video to find out how. #Livecyte #TCells #CancerResearch #Oncology

Not all cells act the same! The cell in this video shows very little T-cell interaction and takes a lot longer to reach cell death. Livecyte can monitor these differences per cell and give population metrics based on the number and the time T cells are bound. Learn how Livecyte can quantify population heterogeneity in T cell: target cell interactions 👇 #Cells #Livecyte #Oncology #TCells #CancerResearch

Learn from RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using irRECIST to assess tumor burden. https://lnkd.in/ekZYn6Jx #MedicalImaging #ClinicalTrials #ChooseCalyx #ESMO2023 

The identification of genetic alterations in soft tissue sarcoma has led to the rise of targeted therapy, significantly expanding the therapeutic landscape. Remaining up to date on emerging data is crucial. #SarcomaAwarenessMonth #OncologyEducation #Oncology

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/dDNPSurm #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using irRECIST to assess tumor burden. https://lnkd.in/gRETtG7E #MedicalImaging #ClinicalTrials #ChooseCalyx #ASCO23 

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/gpsgc4Dy #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/gW7dhgH5 #MedicalImaging #ClinicalTrials #ChooseCalyx